These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9468586)

  • 1. Effects of interleukin-2 for the treatment of malignant mesothelioma.
    Nano R; Capelli E; Civallero M; Terzuolo G; Volpini E; Nascimbene C; Cremaschi P
    Oncol Rep; 1998; 5(2):489-92. PubMed ID: 9468586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
    Lucchi M; Picchi A; Alí G; Chella A; Guglielmi G; Cristaudo A; Fontanini G; Mussi A
    Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):572-6. PubMed ID: 20053697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
    Ampollini L; Soltermann A; Felley-Bosco E; Lardinois D; Arni S; Speck RF; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):457-62. PubMed ID: 19162494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
    Anraku M; Cunningham KS; Yun Z; Tsao MS; Zhang L; Keshavjee S; Johnston MR; de Perrot M
    J Thorac Cardiovasc Surg; 2008 Apr; 135(4):823-9. PubMed ID: 18374762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
    Astoul P; Bertault-Peres P; Durand A; Boutin C
    Rev Mal Respir; 1994; 11(1):29-35. PubMed ID: 8128091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Eosinophil colony stimulating activity induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy].
    Nakamura Y; Ozaki T; Kamei T; Kawaji K; Fujisawa K; Nii A; Yanagawa H; Nishioka Y; Shimizu E; Sone S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Oct; 28(10):1314-20. PubMed ID: 2273659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
    Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
    Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
    Halme M; Knuuttila A; Vehmas T; Tammilehto L; Mäntylä M; Salo J; Mattson K
    Br J Cancer; 1999 Aug; 80(11):1781-5. PubMed ID: 10468296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
    Sterman DH; Molnar-Kimber K; Iyengar T; Chang M; Lanuti M; Amin KM; Pierce BK; Kang E; Treat J; Recio A; Litzky L; Wilson JM; Kaiser LR; Albelda SM
    Cancer Gene Ther; 2000 Dec; 7(12):1511-8. PubMed ID: 11228529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
    Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
    Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
    Clayton A; Mitchell JP; Court J; Mason MD; Tabi Z
    Cancer Res; 2007 Aug; 67(15):7458-66. PubMed ID: 17671216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
    Ribi K; Bernhard J; Schuller JC; Weder W; Bodis S; Jörger M; Betticher D; Schmid RA; Stupp R; Ris HB; Stahel RA;
    Lung Cancer; 2008 Sep; 61(3):398-404. PubMed ID: 18433927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.
    Sosman JA; Bartemes K; Offord KP; Kita H; Fisher SG; Kefer C; Ellis TA; Fisher RI; Higgins TJ; Gleich GJ
    Clin Cancer Res; 1995 Aug; 1(8):805-12. PubMed ID: 9816049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.